What should a drug company do if it spends millions of dollars on a compound and it doesn’t do anything? Easy: (Click on the panel to see the whole cartoon.) In fact, I’m surprised more pharmaceutical companies don’t do this…
Category: Clinical trials
One reason I (and most people involved in cancer research) don’t like the frequently used term “cure for cancer.” The reason is simple. Embedded within this term is the assumption that cancer is just one disease, when it is most definitely not. Rather, it is many diseases affecting many organs, each with its own mechanism […]
Share this:
I have to hand it to acupuncture mavens. They are persistent. Despite numerous studies failing to find any evidence that acupuncture is anything more than an elaborate placebo whose effects, such as they are, derive from nonspecifice mechanisms having nothing to do with meridians, qi, or “unblocking” qi. Moreover, consistent with the contention that acupuncture […]
Share this:
Remember about a week ago, when I lamented how scientific publisher Elsevier had created a fake journal for Merck that reprinted content from other Elsevier journals favorable to Merck products in a format that looked every bit like a peer-reviewed journal but without any disclaimers to let the unwary know that it wasn’t a peer-reviewed […]
Share this:
It’s times like these when I’m happy that I haven’t published in too many Elsevier Journals during the course of my career. I say that because on Thursday, it was revealed that pharmaceutical company Merck, Sharp & Dohme paid Elsevier to produce a fake medical journal that, to any superficial examination, looked like a real […]
